Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5YK | ISIN: US57055L2060 | Ticker-Symbol: GX1
Frankfurt
28.03.24
16:51 Uhr
3,980 Euro
+0,140
+3,65 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MARKER THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
MARKER THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur MARKER THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M5
MoMarker Therapeutics Reports Year-End 2023 Corporate and Financial Results70Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following...
► Artikel lesen
FrMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference3
26.02.Marker Therapeutics, Inc. - 8-K, Current Report1
22.01.Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-6012
08.01.Marker Therapeutics, Inc. - 8-K, Current Report2
08.01.Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization197Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...
► Artikel lesen
08.01.Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization1
05.01.XFRA DIVERSE: WIEDERAUFNAHME/RESUMPTION1.126FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
21.12.23Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During "J.P. Morgan Week 2024"4
12.12.23PSTX, MRKR and GPRO among pre-market losers3
11.12.23GTHX, MRKR and CLIR among mid-day movers12
11.12.23Marker Therapeutics, Inc. - 8-K, Current Report4
20.11.23Marker Therapeutics, Inc. - 8-K, Current Report4
10.11.23Marker Therapeutics GAAP EPS of -$0.34, revenue of $257.61M4
09.11.23Marker Therapeutics, Inc. - 8-K, Current Report3
09.11.23Marker Therapeutics, Inc. - 10-Q, Quarterly Report2
09.11.23Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates213Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...
► Artikel lesen
14.08.23Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update413Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...
► Artikel lesen
07.08.23Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program302HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1